A Novel Biosensor System on Microfluidic Platform for Diagnosis of Breast Cancer

Breast cancer still imposes a significant health burden on women worldwide. As is true with most other cancer diseases, early diagnosis and implementation of prompt treatment are crucial in battling this disease. Biological markers from blood, urine, and tissue can signal predisposition, onset, response to drug treatment, and recurrence of breast cancer. Thus discovery and early detection of biomarkers are among the techniques that play significant roles in early diagnosis, effective prognosis, and close monitoring in treatment of breast cancers. Genomic and proteomic-based biomarkers are the most widely studied tumor markers for early detection of cancers; genomic biomarkers are the genetic mutations or alterations in specific genes, while proteomic biomarkers are the changes in protein shape, function, and pattern of expression due to cancerous conditions.